Literature DB >> 16242977

Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action.

K Rutten1, J Prickaerts, A Blokland.   

Abstract

In this study, the effect of the selective phosphodiesterase type 4 (PDE4) inhibitor rolipram on memory performance was investigated using the object recognition task. First, three doses of rolipram (0.01, 0.03 or 0.1 mg/kg) were tested with a 24h delay between the learning (T1) and the test (T2) trial. Doses of rolipram were injected at different time points (30 min before T1, immediately after T1 or 3 h after T1). In a second experiment, the effects of rolipram (0.03, 0.1 or 0.3 mg/kg) were tested in combination with scopolamine (0.1 mg/kg) applying a 1 h delay between trials. Both substances were administered 30 min before T1. Using a 24h interval, rolipram showed an improvement in long-term memory performance when injected 3 h after T1 at a dose of 0.03 mg/kg. Further, rolipram reversed the scopolamine-induced short-term memory deficit at a dose of 0.1 mg/kg. Although the improved memory performance in both conditions is likely to be explained by elevated cAMP levels, two separate working mechanisms might explain these effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16242977     DOI: 10.1016/j.nlm.2005.09.002

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  37 in total

1.  Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats.

Authors:  Yu-Fang Cheng; Chuang Wang; Huan-Bing Lin; Yun-Feng Li; Ying Huang; Jiang-Ping Xu; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2010-07-17       Impact factor: 4.530

Review 2.  PDE4 as a target for cognition enhancement.

Authors:  Wito Richter; Frank S Menniti; Han-Ting Zhang; Marco Conti
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

Review 3.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

4.  Anticholinergic Amnesia is Mediated by Alterations in Human Network Connectivity Architecture.

Authors:  Jasmeer P Chhatwal; Aaron P Schultz; Trey Hedden; Brendon P Boot; Sarah Wigman; Dorene Rentz; Keith A Johnson; Reisa A Sperling
Journal:  Cereb Cortex       Date:  2019-07-22       Impact factor: 5.357

5.  Inhibition of phosphodiesterase-4 reverses the cognitive dysfunction and oxidative stress induced by Aβ25-35 in rats.

Authors:  Yeye Zhuo; Haibiao Guo; Yufang Cheng; Chuang Wang; Canmao Wang; Jingang Wu; Zhengqiang Zou; Danna Gan; Yiwen Li; Jiangping Xu
Journal:  Metab Brain Dis       Date:  2016-02-27       Impact factor: 3.584

6.  Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling.

Authors:  Eva Bollen; Daniela Puzzo; Kris Rutten; Lucia Privitera; Jochen De Vry; Tim Vanmierlo; Gunter Kenis; Agostino Palmeri; Rudi D'Hooge; Detlef Balschun; Harry M W Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Neuropsychopharmacology       Date:  2014-05-12       Impact factor: 7.853

Review 7.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Administration of phosphodiesterase inhibitors and an adenosine A1 receptor antagonist induces phrenic nerve recovery in high cervical spinal cord injured rats.

Authors:  S Kajana; H G Goshgarian
Journal:  Exp Neurol       Date:  2008-01-05       Impact factor: 5.330

9.  Differential novelty detection in rats selectively bred for novelty-seeking behavior.

Authors:  Santiago J Ballaz
Journal:  Neurosci Lett       Date:  2009-06-02       Impact factor: 3.046

Review 10.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.